Clinical Care and Research

Robert A. Colbert, M.D., Ph.D.

Overview

Clinical Director

Research Areas (IRP Lab Groups)

The NIAMS Clinical Care and Research Programs, based on the NIH campus in Bethesda, Maryland, focus on rheumatologic, musculoskeletal, skin, and inflammatory diseases. 

As part of the NIH Intramural Research Program, NIAMS conducts in-depth clinical and translational research at the NIH Clinical Center, advancing understanding and treatment of conditions such as lupus, rheumatoid arthritis, autoinflammatory diseases, myositis, vasculitis, and related disorders—including rare diseases.

Multidisciplinary teams provide comprehensive evaluation and coordinated care, particularly for patients in the Maryland, Virginia, and DC region, while also training the next generation of physician-scientists. 

Interpretation services, local travel assistance, and collaboration with primary and specialty providers support both research participation and long-term disease management.

Translational Research: The Bridge Between Basic Research and Clinical Disease

Translational research connects laboratory discoveries with clinical practice. Through well-designed observational and interventional studies, it validates biological insights in patients and returns new knowledge to the lab about the mechanisms underlying health and disease.

Training Programs

The NIAMS Clinical Research Program includes the following:

Dermatology Consultation Service

The Dermatology Consultation Service at the NIH Clinical Center evaluates patients enrolled in NIH clinical research protocols, including those with rare diseases affecting the skin and adverse reactions to experimental therapies. The service also provides training for Dermatology Branch fellows, fellows from other NIH Institutes, and visiting dermatology residents nationwide. Notably, cases evaluated by the service are featured in the Journal of the American Academy of Dermatology through its “Grand Rounds at the NIH” series.

NIAMS Community Health Clinic (CHC)

In addition to its disease-focused clinical research programs, the CHC provides specialist care and screening for participation in clinical research studies for patients in the local area with serious rheumatological conditions. The clinic is located on the NIH campus in Bethesda, Maryland.

Clinical Trials

Natural History Studies: follow people who have, or may develop, a disease to learn how it changes over time. They do not test new treatments, but patients may still receive standard medical care. 

These studies help doctors and researchers better understand diseases and improve how they are diagnosed, prevented, and treated.

The NIAMS Clinical Research Program (CRP) conducts natural history and observational studies of skin (dermatology), joints (rheumatology), muscle (myology), blood vessels (angiology), bones (osteology), and autoimmunity. 

Some studies focus on specific diseases, including spondyloarthritis, systemic juvenile idiopathic arthritis, lupus, myositis, vasculitis, melorheostosis, dermatitis, alopecia, and COVID-19.

For additional information, please search the database of all clinical studies being conducted at the NIH Clinical Center.

Current NIAMS Natural History and Observational Studies

Autoimmune Diseases

Completed
ClinicalTrials.gov Identifier: NCT05502796
Dr. Leslie Castelo-Soccio is the Principal Investigator of this study. Alopecia is the loss of hair or lack of hair growth.
Recruiting
ClinicalTrials.gov Identifier: NCT01422694
Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis, and outcome.
Completed
ClinicalTrials.gov Identifier: NCT04690816 
This is an observational study to characterize how COVID-19 modulates systemic inflammation, autoimmune features and vasculopathy in adult and pediatric patients with a prior diagnosis of systemic autoimmunity, and their overall outcomes including response to potential antiviral treatments or vaccines.
Completed
ClinicalTrials.gov Identifier: NCT02338999
Researchers want to see if the drug pioglitazone may help and to see how well pioglitazone improves blood vessel function and decreases blood vessel inflammation.

Systemic Lupus Erythematosus (Lupus)

Recruiting
ClinicalTrials.gov Identifier: NCT05440422 
This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with systemic lupus erythematosus (SLE).
Recruiting
ClinicalTrials.gov Identifier: NCT05567198 
Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. People with SLE are often treated with cyclophosphamide (CYC). But CYC can damage a woman s ovaries; it may cause infertility. A drug called GnRHa is sometimes given to protect the ovaries during CYC therapy. But no one really knows how effective GnRHa treatment is. This natural history survey will compare women who received GnRHa during CYC therapy with those who did not.
Recruiting
ClinicalTrials.gov Identifier: NCT00001372
This study enrolls patients with systemic lupus erythematosus. The goal is to identify clinical subsets of patient that might aid in understanding progress and determining appropriate therapies. The goals of this research study are to evaluate patients thought to have the disease to better understand how the disease begins and how it affects patients. Secondly, to follow patients during the course of the disease to understand how the disease changes over time and the effects of standard treatments.

Rheumatic Diseases

Recruiting
ClinicalTrials.gov Identifier: NCT02504879
The rare disease melorheostosis causes bones to thicken. This may lead to pain, and can affect bones, joints, and muscles. Researchers want to learn more about the disease and how it progresses.
Recruiting
ClinicalTrials.gov Identifier: NCT00024479
This study will explore the causes of rheumatic diseases and why many of them affect certain communities more severely.

Tumor Necrosis Factor Receptor-Associated Periodic Syndrome

Active, not recruiting
ClinicalTrials.gov Identifier: NCT01793519
Researchers want to see if people with RA in remission on a TNF inhibitor can stay in remission without this medicine. Also there may be a clinical, imaging (MRI, ultrasound), laboratory profile that will help to determine which patients remain in remission after stopping these drugs. This study will provide important new information on the best treatment approach for patients with RA in remission.

Dermatomyositis

Completed
ClinicalTrials.gov Identifier: NCT00001265
This study of inflammatory muscle diseases-polymyositis and dermatomyositis and related disorders-will examine what causes these diseases and describe the clinical features (signs and symptoms) associated with them.

Myopathy

Recruiting
ClinicalTrials.gov Identifier: NCT05738824
This is an observational study to characterize the different types of inflammatory myopathies, understand their etiology, pathogenesis, prognosis, and response to different treatments. 

Vasculitis

Recruiting
ClinicalTrials.gov Identifier: NCT02257866
Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse. Researchers want to study people s genes and follow people over time to see how the disease affects them.

Skin Diseases

Recruiting
ClinicalTrials.gov Identifier: NCT02471352
Skin diseases represent one of the most common medical problems in the United States, affecting 1 in 3 people at any given time. This study aims to procure biologic samples for exploratory cellular, molecular, genetic and genomic biological studies from subjects with dermatologic conditions, subjects at risk for developing dermatologic conditions and healthy volunteers in the support of NIH biomedical studies.
Recruiting
ClinicalTrials.gov Identifier: NCT01631617
Atopic dermatitis, or eczema, is a chronic skin disorder. The use of antibiotics has revolutionized medicine, yet the impact of antimicrobials on the human microbiome is incompletely understood. This study aims to characterize microbiome alterations in healthy adult volunteers and patients with atopic dermatitis after antimicrobial treatments.

Systemic Arthritis and Autoinflammation

Recruiting
ClinicalTrials.gov Identifier: NCT03510442
Inflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD). Their causes are unknown. Researchers want to learn more about these conditions. This includes genetic changes and environmental factors.

Scientific Publications

Selected Recent Publications

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA
Ann Rheum Dis.
2021 Mar;
80(3).
doi: 10.1136/annrheumdis-2020-218690
PMID: 32843325

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R
J Clin Invest.
2018 Jul 2;
128(7).
doi: 10.1172/JCI98814
PMID: 29649002

Germline gain-of-function myeloid differentiation primary response gene-88 (MYD88) mutation in a child with severe arthritis.

Sikora KA, Bennett JR, Vyncke L, Deng Z, Tsai WL, Pauwels E, Layh-Schmitt G, Brundidge A, Navid F, Zaal KJM, Hanson E, Gadina M, Staudt LM, Griffin TA, Tavernier J, Peelman F, Colbert RA
J Allergy Clin Immunol.
2018 May;
141(5).
doi: 10.1016/j.jaci.2018.01.027
PMID: 29427642

Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus.

Carlucci PM, Purmalek MM, Dey AK, Temesgen-Oyelakin Y, Sakhardande S, Joshi AA, Lerman JB, Fike A, Davis M, Chung JH, Playford MP, Naqi M, Mistry P, Gutierrez-Cruz G, Dell'Orso S, Naz F, Salahuddin T, Natarajan B, Manna Z, Tsai WL, Gupta S, Grayson P, Teague H, Chen MY, Sun HW, Hasni S, Mehta NN, Kaplan MJ
JCI Insight.
2018 Apr 19;
3(8).
pii: 99276. doi: 10.1172/jci.insight.99276
PMID: 29669944

IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.

Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM, INCHARGE Consortium, Thomson W, Kastner DL, Woo P, Ombrello MJ
Arthritis Rheumatol.
2018 Aug;
70(8).
doi: 10.1002/art.40498
PMID: 29609200

(18) F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis.

Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, Malayeri AA, Merkel PA, Novakovich E, Bluemke DA, Ahlman MA
Arthritis Rheumatol.
2018 Mar;
70(3).
doi: 10.1002/art.40379
PMID: 29145713

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P
J Immunother Cancer.
2018 Jan 19;
6(1).
doi: 10.1186/s40425-017-0310-x
PMID: 29347993

STAT5B: A Differential Regulator of the Life and Death of CD4(+) Effector Memory T Cells.

Majri SS, Fritz JM, Villarino AV, Zheng L, Kanellopoulou C, Chaigne-Delalande B, Grönholm J, Niemela JE, Afzali B, Biancalana M, Pittaluga S, Sun A, Cohen JL, Holland SM, O'Shea JJ, Uzel G, Lenardo MJ
J Immunol.
2018 Jan 1;
200(1).
doi: 10.4049/jimmunol.1701133
PMID: 29187589

BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency.

Afzali B, Grönholm J, Vandrovcova J, O'Brien C, Sun HW, Vanderleyden I, Davis FP, Khoder A, Zhang Y, Hegazy AN, Villarino AV, Palmer IW, Kaufman J, Watts NR, Kazemian M, Kamenyeva O, Keith J, Sayed A, Kasperaviciute D, Mueller M, Hughes JD, Fuss IJ, Sadiyah MF, Montgomery-Recht K, McElwee J, Restifo NP, Strober W, Linterman MA, Wingfield PT, Uhlig HH, Roychoudhuri R, Aitman TJ, Kelleher P, Lenardo MJ, O'Shea JJ, Cooper N, Laurence ADJ
Nat Immunol.
2017 Jul;
18(7).
doi: 10.1038/ni.3753
PMID: 28530713

Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis.

Byrd AL, Deming C, Cassidy SKB, Harrison OJ, Ng WI, Conlan S, NISC Comparative Sequencing Program, Belkaid Y, Segre JA, Kong HH
Sci Transl Med.
2017 Jul 5;
9(397).
doi: 10.1126/scitranslmed.aal4651
PMID: 28679656

Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim.

Tan S, Dasgupta A, Yao J, Flynn JA, Yao L, Ward MM
Ann Rheum Dis.
2016 Nov;
75(11).
doi: 10.1136/annrheumdis-2015-208802
PMID: 26797721
Last Updated: March 2026